37,012 Shares in Astera Labs, Inc. $ALAB Purchased by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA acquired a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 37,012 shares of the company’s stock, valued at approximately $7,247,000.

Several other institutional investors have also recently made changes to their positions in the company. Oliver Lagore Vanvalin Investment Group purchased a new stake in Astera Labs during the second quarter worth $29,000. Bernard Wealth Management Corp. acquired a new position in shares of Astera Labs in the second quarter worth about $36,000. Clearstead Trust LLC raised its position in shares of Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock worth $42,000 after acquiring an additional 461 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Astera Labs by 68.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock worth $43,000 after acquiring an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC grew its position in shares of Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after acquiring an additional 283 shares during the period. 60.47% of the stock is owned by hedge funds and other institutional investors.

Astera Labs Price Performance

Shares of Astera Labs stock opened at $144.94 on Wednesday. The stock has a market capitalization of $24.48 billion, a P/E ratio of 130.58, a PEG ratio of 2.68 and a beta of 1.51. The business has a 50 day simple moving average of $163.73 and a two-hundred day simple moving average of $154.73. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.39 by $0.10. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The firm had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. During the same period in the previous year, the business earned $0.23 earnings per share. The firm’s revenue for the quarter was up 103.9% on a year-over-year basis. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, research analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other news, CFO Michael Truett Tate sold 11,430 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $1,653,806.70. Following the completion of the sale, the chief financial officer directly owned 192,297 shares in the company, valued at $27,823,452.93. This represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Manuel Alba sold 150,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the completion of the transaction, the director directly owned 1,574,498 shares in the company, valued at approximately $261,650,077.64. This represents a 8.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 586,936 shares of company stock valued at $89,331,140. 12.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALAB. TD Cowen reduced their price target on Astera Labs from $225.00 to $170.00 and set a “hold” rating for the company in a report on Wednesday, November 5th. Roth Capital boosted their price objective on Astera Labs from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Bank of America assumed coverage on Astera Labs in a research note on Friday, October 3rd. They set a “neutral” rating and a $230.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Astera Labs in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus boosted their price target on shares of Astera Labs from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Astera Labs has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.